About Onconetix, Inc. Common Stock
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Market Cap
$0.00B
Employees
12
Listed Since
February 18, 2022
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.onconetix.comPhone
513-620-4101
Headquarters
201 E. FIFTH STREET
CINCINNATI, OH 45202
CIK
0001782107